Growth hormone-releasing factor modifies dopaminergic but not serotonergic activity in the arcuate nucleus of hypothalamus in the rat, as recorded in vivo by differential pulse voltammetry.
Parenteral (i.v.) injection of growth hormone-releasing factor (GRF) increases the height of the 3,4-dihydroxyphenylacetic acid oxidation peak (peak 2) but does not change 5-hydroxyindole extracellular content (peak 3) in the arcuate nucleus of the hypothalamus, both peaks being recorded by the differential pulse voltammetry technique using a single specifically pretreated monopyrolytic carbon fibre electrode. Conversely, no significant changes are observed in the peak 2 and peak 3 heights recorded in the medial or in the lateral nucleus of the hypothalamus. These data suggest a specific interaction between GRF and the dopaminergic system.
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D004563:Electrochemistry; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D009474:Neurons / Q000378:metabolism; D051381:Rats; D012701:Serotonin / Q000378:metabolism*; D013997:Time Factors
D012701:Serotonin; D013007:Growth Hormone-Releasing Hormone; D004298:Dopamine